Results 211 to 220 of about 22,015 (248)
Cost-utility and budget impact analysis of biosimilar trastuzumab for early-stage HER2-positive breast cancer in Thailand: an updated evaluation supporting expanded access. [PDF]
BMC Health Serv ResLochid-Amnuay S, Kongsakon R.
europepmc +1 more source
Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.
JAMA Netw OpenAbdelaziz A +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
International Journal of Nutrition, Pharmacology, Neurological Diseases, 2021
Biologics are medicines primarily derived from living systems and produced through recombinant DNA (rDNA) and monoclonal technologies. Generic version of biologics with improved efficacy and safety is called biosimilar. Patent and copyright expiration of biological products permits the entry of biosimilars.
Saravanan Bhojaraj +10 more
openaire +2 more sources
Biologics are medicines primarily derived from living systems and produced through recombinant DNA (rDNA) and monoclonal technologies. Generic version of biologics with improved efficacy and safety is called biosimilar. Patent and copyright expiration of biological products permits the entry of biosimilars.
Saravanan Bhojaraj +10 more
openaire +2 more sources
European Journal of Hospital Pharmacy, 2019
Biological medicines have become indispensable in the treatment of patients with serious diseases such as cancer and inflammatory diseases. Biosimilars are medicines which are developed to be similar to existing biological medicines (the 'reference product'). For the European market, they are approved by the European Medicines Agency.
András Süle +4 more
openaire +2 more sources
Biological medicines have become indispensable in the treatment of patients with serious diseases such as cancer and inflammatory diseases. Biosimilars are medicines which are developed to be similar to existing biological medicines (the 'reference product'). For the European market, they are approved by the European Medicines Agency.
András Süle +4 more
openaire +2 more sources
Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies
Drug Metabolism and Pharmacokinetics, 2019 The concept of biosimilar was established in the early 2000s in EU. Currently, the regulatory framework for biosimilar has also been established in the US, Japan, and other countries. As of 2018, biosimilars for infliximab, adalimumab, rituximab, trastuzumab, and bevacizumab have been approved.
Akiko, Ishii-Watabe, Takashi, Kuwabara
exaly +3 more sources
Expert Opinion on Biological Therapy, 2012
Until now most insulin used in developed countries is manufactured and distributed by a small number of multinational companies. Other pharmaceutical companies - many of these are located in countries such as India or China - are also able to manufacture insulin with modern biotechnological methods.
openaire +2 more sources
Until now most insulin used in developed countries is manufactured and distributed by a small number of multinational companies. Other pharmaceutical companies - many of these are located in countries such as India or China - are also able to manufacture insulin with modern biotechnological methods.
openaire +2 more sources